Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O1KX
|
|||
| Former ID |
DNC000265
|
|||
| Drug Name |
Avasimibe
|
|||
| Synonyms |
Avasimibe; 166518-60-1; CI-1011; Avasimibe(CI-1011); UNII-28LQ20T5RC; CI 1011; Avasimibe (CI-1011); PD 148515; CHEMBL101309; 28LQ20T5RC; 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate; 2,6-diisopropylphenyl 2-(2,4,6-triisopropylphenyl)acetylsulfamate; 2,6-Diisopropylphenyl ((2,4,6-triisopropylphenyl)acetyl)sulfamate; 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)-acetyl)sulfamate; ((2,4,6-Tris(1-methylethyl)phenyl)acetyl)sulfamic acid 2,6-bis(1-methylethyl)phenyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Peripheral vascular disease [ICD-11: BD4Z; ICD-10: I73.9; ICD-9: 443.9] | Discontinued in Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H43NO4S
|
|||
| Canonical SMILES |
CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C
|
|||
| InChI |
1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)
|
|||
| InChIKey |
PTQXTEKSNBVPQJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 166518-60-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10256123, 12014930, 14786561, 17397168, 46240223, 49878439, 51696037, 53789929, 57350929, 93167047, 103111786, 103315998, 103963862, 104253507, 113458560, 117634678, 124757631, 125164435, 125655156, 126661326, 126681655, 128966690, 134339734, 135121138, 135374372, 135727829, 136340367, 136367465, 136920275, 137262947, 137267096, 142549536, 143493389, 144115648, 152053404, 152234929, 152344251, 162011453, 162037802, 162189205, 163908017, 164043012, 174006553, 174527851, 176225440, 179150041, 186014461, 198989658, 223393138, 223536012
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Liver carboxylesterase (CES1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Drug metabolism - other enzymes | |||
| Metabolic pathways | ||||
| Pathway Interaction Database | E2F transcription factor network | |||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Heroin metabolism | ||||
| Irinotecan Pathway | ||||
| Fluoropyrimidine Activity | ||||
| Phase I biotransformations, non P450 | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008778) | |||
| REF 2 | New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.